Literature DB >> 12217521

The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network.

Lindsey D Mayo1, David B Donner.   

Abstract

Oncoproteins and tumor-suppressor proteins regulate cell growth and viability. Recent observations show that phosphoinositide 3-kinase (PtdIns 3-kinase)-Akt signaling promotes the phosphorylation and movement of the Mdm2 oncoprotein into the nucleus, where it downregulates the p53 tumor-suppressor protein. The PTEN tumor suppressor protein inhibits activation of Akt and this restricts Mdm2 to the cytoplasm. Restriction of Mdm2 to the cytoplasm promotes p53 function and thereby sustains the sensitivity of cancer cells to chemotherapy. p53 acutely induces Mdm2, providing damaged cells the opportunity for repair, but subsequently induces PTEN, favoring the death of mutated or irrevocably damaged cells. Thus, oncoproteins and tumor suppressor proteins are networked to promote normal cell function and eliminate mutated cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12217521     DOI: 10.1016/s0968-0004(02)02166-7

Source DB:  PubMed          Journal:  Trends Biochem Sci        ISSN: 0968-0004            Impact factor:   13.807


  126 in total

1.  Apoptosis induced by ZnPcH1-based photodynamic therapy in Jurkat cells and HEL cells.

Authors:  Huifang Huang; Xiaoyan Zhao; Yuanzhong Chen; Rong Lu; Yong Wu
Journal:  Int J Hematol       Date:  2011-11-17       Impact factor: 2.490

2.  Oestrogen prevents cardiomyocyte apoptosis by suppressing p38α-mediated activation of p53 and by down-regulating p53 inhibition on p38β.

Authors:  Han Liu; Ali Pedram; Jin Kyung Kim
Journal:  Cardiovasc Res       Date:  2010-08-19       Impact factor: 10.787

3.  Tight regulation of p53 activity by Mdm2 is required for ureteric bud growth and branching.

Authors:  Sylvia Hilliard; Karam Aboudehen; Xiao Yao; Samir S El-Dahr
Journal:  Dev Biol       Date:  2011-03-21       Impact factor: 3.582

4.  Anti-cancer activities of tea epigallocatechin-3-gallate in breast cancer patients under radiotherapy.

Authors:  G Zhang; Y Wang; Y Zhang; X Wan; J Li; K Liu; F Wang; K Liu; Q Liu; C Yang; P Yu; Y Huang; S Wang; P Jiang; Z Qu; J Luan; H Duan; L Zhang; A Hou; S Jin; T-C Hsieh; E Wu
Journal:  Curr Mol Med       Date:  2012-02       Impact factor: 2.222

5.  Urothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies.

Authors:  Haiping Zhou; Hong-ying Huang; Ellen Shapiro; Herbert Lepor; William C Huang; Moosa Mohammadi; Ian Mohr; Moon-shong Tang; Chuanshu Huang; Xue-ru Wu
Journal:  Carcinogenesis       Date:  2012-01-27       Impact factor: 4.944

6.  Qualitative network modeling of the Myc-p53 control system of cell proliferation and differentiation.

Authors:  Baltazar D Aguda; Yangjin Kim; Hong Sug Kim; Avner Friedman; Howard A Fine
Journal:  Biophys J       Date:  2011-11-01       Impact factor: 4.033

7.  Nuclear localization of PTEN by a Ran-dependent mechanism enhances apoptosis: Involvement of an N-terminal nuclear localization domain and multiple nuclear exclusion motifs.

Authors:  Anabel Gil; Amparo Andrés-Pons; Elena Fernández; Miguel Valiente; Josema Torres; Javier Cervera; Rafael Pulido
Journal:  Mol Biol Cell       Date:  2006-06-28       Impact factor: 4.138

8.  Dysregulated TCL1 requires the germinal center and genome instability for mature B-cell transformation.

Authors:  Rhine R Shen; David O Ferguson; Mathilde Renard; Katrina K Hoyer; Unkyu Kim; Xingpei Hao; Frederick W Alt; Robert G Roeder; Herbert C Morse; Michael A Teitell
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

9.  Helicobacter pylori Infection Activates the Akt-Mdm2-p53 Signaling Pathway in Gastric Epithelial Cells.

Authors:  Xu Shu; Zhen Yang; Zhong-Hua Li; Lian Chen; Xiao-Dong Zhou; Yong Xie; Nong-Hua Lu
Journal:  Dig Dis Sci       Date:  2014-12-06       Impact factor: 3.199

Review 10.  Inhibiting PI3K as a therapeutic strategy against cancer.

Authors:  Luis Paz-Ares; Carmen Blanco-Aparicio; Rocío García-Carbonero; Amancio Carnero
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.